Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May 5;6(3):182-190.
doi: 10.1158/2643-3230.BCD-24-0178.

Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

Nora Liebers  1   2   3   4 , Ariane Boumendil  5 , Hervé Finel  5 , Dominic Edelmann  6 , Guido Kobbe  1   3 , Ben-Niklas Baermann  1   3 , Yasmina Serroukh  7 , Didier Blaise  8 , Dietrich Wilhelm Beelen  9 , Carlos Solano  10 , Maija Itälä-Remes  11 , Tom van Meerten  12 , Goda Choi  12 , Susanne Anna Christine Schmidt  1   3 , Nicolaus Kröger  13 , Jenny Byrne  14 , Jean-Jacques Tudesq  15 , Anna Ossami Saidy  16 , Ana Nunes  17 , Rubina Siddiqi  17 , Elande Baro  17 , Dan Zheng  17 , Ioana Kloos  17 , Peter Dreger  4   5 , Anna Sureda  5   18 , Bertram Glass #  5   16 , Sascha Dietrich #  1   3   4   5
Affiliations

Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma

Nora Liebers et al. Blood Cancer Discov. .

Abstract

Patients aged ≥50 years with r/r MCL had superior OS and lower nonrelapse mortality 1 year after receiving brexu-cel compared with alloHCT. However, the long-term PFS and OS are similar for both treatments. Individual risk-benefit evaluation is essential to guide optimal treatment decisions.

PubMed Disclaimer

Conflict of interest statement

N. Liebers reports grants and personal fees from the National Center for Tumor Diseases Heidelberg during the conduct of the study, as well as personal fees from BeiGene and nonfinancial support from Janssen outside the submitted work. G. Kobbe reports personal fees from Gilead/Kite Pharma during the conduct of the study. B.-N. Baermann reports personal fees and nonfinancial support from Gilead/Kite Pharma during the conduct of the study, as well as personal fees from Medac, BeiGene, and Incyte outside the submitted work. Y. Serroukh reports other support from Gilead/Kite Pharma outside the submitted work. D. Blaise reports grants and other support from Jazz Pharmaceuticals outside the submitted work. T. van Meerten reports grants from Genentech and Siemens, grants and personal fees from Celgene/Bristol Myers Squibb, and personal fees from Gilead/Kite Pharma and Janssen outside the submitted work. S.A.C. Schmidt reports nonfinancial support (paid travel/congress) from Janssen. J.-J. Tudesq reports personal fees from Bristol Myers Squibb, Gilead, and Roche outside the submitted work. A. Ossami Saidy reports personal fees from Gilead/Kite Pharma outside the submitted work. A. Nunes reports personal fees from Gilead Sciences outside the submitted work. R. Siddiqi reports other support from Gilead/Kite Pharma outside the submitted work. A. Sureda reports other support from Takeda, Bristol Myers Squibb/Celgene, MSD, Janssen, Amgen, Novartis, Gilead/Kite Pharma, Sanofi, Roche, and Alexion and holding presidency of the Grupo Español de Trasplante Hematopoyético y Terapia Celular and presidency of the European Society for Blood and Marrow Transplantation outside the submitted work. B. Glass reports personal fees from Gilead/Kite Pharma during the conduct of the study, as well as personal fees from Bristol Myers Squibb, Novartis and Miltenyi Biotec and grants and personal fees from Roche outside the submitted work. No disclosures were reported by the other authors.

References

    1. Alaggio R, Amador C, Anagnostopoulos I, Attygalle AD, de Oliveira Araujo IB, Berti E, et al. . The 5th edition of the world health organization classification of haematolymphoid tumours: lymphoid neoplasms. Leukemia 2022;36:1720–48. - PMC - PubMed
    1. Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, et al. . Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. Lancet 2018;391:659–67. - PMC - PubMed
    1. Wang ML, Rule S, Martin P, Goy A, Auer R, Kahl BS, et al. . Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med 2013;369:507–16. - PMC - PubMed
    1. Hamadani M, Saber W, Ahn KW, Carreras J, Cairo MS, Fenske TS, et al. . Allogeneic hematopoietic cell transplantation for chemotherapy-unresponsive mantle cell lymphoma: a cohort analysis from the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2013;19:625–31. - PMC - PubMed
    1. Robinson SP, Boumendil A, Finel H, Peggs KS, Chevallier P, Sierra J, et al. . Long-term outcome analysis of reduced-intensity allogeneic stem cell transplantation in patients with mantle cell lymphoma: a retrospective study from the EBMT Lymphoma Working Party. Bone Marrow Transplant 2018;53:617–24. - PubMed

LinkOut - more resources